Divergent effects of genetic and pharmacological inhibition of Nox2 NADPH oxidase on insulin resistance-related vascular damage.


Journal

American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225

Informations de publication

Date de publication:
01 07 2020
Historique:
pubmed: 14 5 2020
medline: 22 10 2020
entrez: 14 5 2020
Statut: ppublish

Résumé

Insulin resistance leads to excessive endothelial cell (EC) superoxide generation and accelerated atherosclerosis. The principal source of superoxide from the insulin-resistant endothelium is the Nox2 isoform of NADPH oxidase. Here we examine the therapeutic potential of Nox2 inhibition on superoxide generation in saphenous vein ECs (SVECs) from patients with advanced atherosclerosis and type 2 diabetes and on vascular function, vascular damage, and lipid deposition in apolipoprotein E-deficient (ApoE

Identifiants

pubmed: 32401607
doi: 10.1152/ajpcell.00389.2019
pmc: PMC7468885
doi:

Substances chimiques

Glycoproteins 0
gp91ds-tat protein, chimeric 0
NADPH Oxidase 2 EC 1.6.3.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

C64-C74

Subventions

Organisme : British Heart Foundation (BHF)
ID : CH/1999001/11735
Pays : International
Organisme : British Heart Foundation
ID : FS/17/66/33480
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/13/1/30086
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/54/30939
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/1999001/11735
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/7/31521
Pays : United Kingdom
Organisme : British Heart Foundation (BHF)
ID : FS/17/66/33480
Pays : International
Organisme : British Heart Foundation (BHF)
ID : CH/13/1/30086
Pays : International
Organisme : British Heart Foundation (BHF)
ID : PG/14/54/30939
Pays : International
Organisme : British Heart Foundation
ID : FS/12/80/29821
Pays : United Kingdom

Références

N Engl J Med. 2010 Dec 30;363(27):2600-10
pubmed: 21190454
Curr Biol. 2014 May 19;24(10):R453-62
pubmed: 24845678
Circ Res. 2010 Oct 29;107(9):1058-70
pubmed: 21030723
Circ Res. 2001 Aug 31;89(5):408-14
pubmed: 11532901
J Clin Invest. 1993 Oct;92(4):1866-74
pubmed: 7691889
Diabetes. 2011 Sep;60(9):2331-40
pubmed: 21752956
Arterioscler Thromb Vasc Biol. 2014 May;34(5):954-8
pubmed: 24740187
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2413-20
pubmed: 25189573
Diabetes. 2017 Nov;66(11):2808-2821
pubmed: 28830894
Free Radic Biol Med. 2011 Sep 15;51(6):1116-25
pubmed: 21586323
Arterioscler Thromb Vasc Biol. 2004 May;24(5):816-23
pubmed: 14976002
Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1311-9
pubmed: 17711985
Clin Sci (Lond). 2016 Apr 1;130(7):479-90
pubmed: 26888560
Diabetes. 2008 Dec;57(12):3307-14
pubmed: 18835939
Lancet. 2006 Jul 1;368(9529):29-36
pubmed: 16815377
Atherosclerosis. 2013 Sep;230(1):131-9
pubmed: 23958265
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
J Cell Biol. 2015 Apr 13;209(1):13-22
pubmed: 25869663
Br J Pharmacol. 2017 Jun;174(12):1533-1554
pubmed: 28332701
Diabetes. 2006 Jan;55(1):209-15
pubmed: 16380495
Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1614-20
pubmed: 15256399
J Innate Immun. 2013;5(6):565-80
pubmed: 23635512
Nat Rev Cardiol. 2020 Apr;17(4):216-228
pubmed: 31578516
Free Radic Biol Med. 2012 Jul 1;53(1):72-80
pubmed: 22583699
Circulation. 2007 Feb 6;115(5):627-37
pubmed: 17242275
Eur Heart J. 2007 Mar;28(5):540-5
pubmed: 17289742
Circ Res. 2017 Mar 3;120(5):784-798
pubmed: 27920123
Arterioscler Thromb. 1994 Oct;14(10):1665-73
pubmed: 7522548
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2143-8
pubmed: 15374850
Circulation. 2013 May 7;127(18):1888-902
pubmed: 23564668
Circulation. 2013 Aug 6;128(6):632-42
pubmed: 23838163
Eur J Pharmacol. 2015 Sep 15;763(Pt A):79-89
pubmed: 26004034
Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):1987-94
pubmed: 26160956
Circulation. 2002 Apr 9;105(14):1656-62
pubmed: 11940543
Diabetes. 2013 Jun;62(6):2130-4
pubmed: 23349484
J Pediatr Gastroenterol Nutr. 2003 May;36(5):623-31
pubmed: 12717086

Auteurs

Azhar Maqbool (A)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Nicole T Watt (NT)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Natalie Haywood (N)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Hema Viswambharan (H)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Anna Skromna (A)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Natalia Makava (N)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Asjad Visnagri (A)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Heba M Shawer (HM)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Katherine Bridge (K)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Shovkat K Muminov (SK)

Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan.

Kathryn Griffin (K)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

David J Beech (DJ)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Stephen B Wheatcroft (SB)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Karen E Porter (KE)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Katie J Simmons (KJ)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Piruthivi Sukumar (P)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Ajay M Shah (AM)

British Heart Foundation, Centre of Research Excellence, King's College London, London, United Kingdom.

Richard M Cubbon (RM)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Mark T Kearney (MT)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Nadira Y Yuldasheva (NY)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH